Market News AIOpen the app

The FDA approved Teva's new treatment IGALMI for use at home to help with agitation in schizophrenia and bipolar disorder.

TrialRead the original at Benzinga
Good for TEVA

FDA approval makes IGALMI the first at-home treatment for sudden agitation tied to schizophrenia, schizoaffective disorder, and bipolar disorder. No patients stopped a 102-person study despite side effects, but Teva paid $57.5 million upfront and may owe up to $67.5 million more.

TEVA · Teva Pharmaceutical Industries Ltd.

AI read · Good for TEVA

The AI's read

The approval gives Teva another way to use a treatment it recently acquired. A 12-week study covered 1,160 agitation episodes among 102 patients, and none stopped treatment because of side effects. Patients reported sleepiness, dry mouth, dizziness, and mouth sensations. Teva also paid $57.5 million upfront and may pay up to $67.5 million more. The new at-home use and study results make this a positive development despite those costs and side effects.

Get alerts for TEVA

Follow Teva Pharmaceutical Industries Ltd. (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TEVA
Free on the App Store and Google Play, or on the web.